Veterinary Clinical Reference
Look up any drug or condition.
Evergreen, evidence-based hubs on the drugs, conditions, and species you manage — continuously updated and cited at every claim.
Tramadol in Dogs and Cats: An Atypical Analgesic With a Critical Species Divide
Tramadol's opioid activity depends on the M1 metabolite dogs barely produce, so oral monotherapy fails for canine osteoarthritis while cats fare better. A clinical review of the evidence, dosing, and interactions.
Read →Meloxicam for Canine Osteoarthritis Pain: Efficacy, Safety, and 2025 Head-to-Head vs. Bedinvetmab
Meloxicam (COX-2 NSAID) equals bedinvetmab for canine OA efficacy in 2025 RCT (n=101), with more GI adverse events. Standard dose: 0.2 mg/kg loading the...
Read →Robenacoxib for Feline Musculoskeletal Pain: COX-2 Selectivity, DJD Evidence, Safety, and the ISFM/AAFP Framework
The evergreen clinical hub on robenacoxib (Onsior) for feline musculoskeletal and DJD pain: COX-2 tissue selectivity and PK, the Adrian 2021 pilot RCT (49% disability reduction, NNT 3.8), King 2021 pooled chronic safety with a CKD subgroup, grapiprant comparator and NSAID-timing data, and the 2024 ISFM/AAFP monitoring framework.
Read →Enflicoxib (Daxocox) for Canine Osteoarthritis: A Once-Weekly COX-2 Selective NSAID
Enflicoxib (Daxocox) is an EU-authorised, once-weekly COX-2 selective NSAID for canine osteoarthritis. This hub reviews its mechanism, 6-month field efficacy and safety (Salichs 2024), long-term durability, comparators, and clinical placement.
Read →Robenacoxib (Onsior) for Pain in Cats and Dogs: COX-2 Selectivity and Clinical Evidence
Robenacoxib (Onsior) is a COX-2-selective NSAID with tissue-preferential distribution. Evidence from a feline DJD RCT and perioperative comparison data reviewed.
Read →Grapiprant (Galliprant) for Canine Osteoarthritis Pain: EP4 Antagonism and Clinical Evidence
Grapiprant (Galliprant) for canine osteoarthritis: EP4 receptor antagonism mechanism, the pivotal JVIM field study (48.1% vs 31.3% success), FDA/EMA approval, meloxicam and firocoxib comparators, RCVS-appraised evidence strength, and multimodal use in young dogs and cats.
Read →Frunevetmab (Solensia) for Feline Osteoarthritis: Efficacy and Real-World Safety
A clinician's evidence hub on frunevetmab (Solensia) for feline OA pain: the Gruen 2021 pivotal RCT and real-world quality-of-life data on efficacy, plus RCT and FDA-database adverse-event signals (predominantly dermatological, with unconfirmed neurological and joint signals).
Read →Librela (Bedinvetmab) in Dogs: Efficacy, Adverse Events & Monitoring
Librela (bedinvetmab) in dogs — side effects, the 2025 musculoskeletal/RPOA safety debate, efficacy vs meloxicam and grapiprant, contraindications, and monitoring. Cited for practitioners.
Read →